Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD16-positive, CD56-dim natural killer cell, human | 7 studies | 18% ± 3% | |
CD8-positive, alpha-beta T cell | 7 studies | 20% ± 5% | |
natural killer cell | 6 studies | 21% ± 3% | |
CD4-positive, alpha-beta T cell | 5 studies | 20% ± 2% | |
regulatory T cell | 5 studies | 17% ± 1% | |
B cell | 4 studies | 18% ± 2% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 21% ± 5% | |
endothelial cell | 4 studies | 20% ± 4% | |
hematopoietic precursor cell | 3 studies | 19% ± 4% | |
fibroblast | 3 studies | 20% ± 3% | |
epithelial cell | 3 studies | 34% ± 15% | |
effector CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
dendritic cell | 3 studies | 27% ± 1% | |
plasmacytoid dendritic cell | 3 studies | 20% ± 2% | |
CD4-positive, alpha-beta memory T cell | 3 studies | 17% ± 1% |
Insufficient scRNA-seq data for expression of RANGRF at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 159.08 | 2639 / 2642 | 96% | 2.49 | 677 / 705 |
prostate | 100% | 225.33 | 245 / 245 | 92% | 2.48 | 464 / 502 |
skin | 100% | 107.39 | 1807 / 1809 | 80% | 1.62 | 379 / 472 |
adrenal gland | 100% | 139.12 | 258 / 258 | 80% | 2.03 | 184 / 230 |
thymus | 100% | 158.13 | 653 / 653 | 80% | 1.77 | 482 / 605 |
bladder | 100% | 192.67 | 21 / 21 | 74% | 1.71 | 372 / 504 |
uterus | 100% | 218.42 | 170 / 170 | 69% | 1.46 | 317 / 459 |
intestine | 100% | 180.14 | 966 / 966 | 63% | 1.33 | 334 / 527 |
breast | 100% | 165.82 | 459 / 459 | 62% | 1.15 | 697 / 1118 |
ovary | 100% | 196.77 | 180 / 180 | 62% | 1.07 | 265 / 430 |
lung | 100% | 154.91 | 578 / 578 | 57% | 1.04 | 662 / 1155 |
stomach | 100% | 162.33 | 359 / 359 | 54% | 1.05 | 155 / 286 |
kidney | 100% | 200.42 | 89 / 89 | 54% | 1.02 | 486 / 901 |
pancreas | 81% | 49.12 | 266 / 328 | 66% | 1.13 | 118 / 178 |
esophagus | 100% | 157.34 | 1440 / 1445 | 31% | 0.46 | 57 / 183 |
liver | 93% | 51.90 | 210 / 226 | 27% | 0.49 | 109 / 406 |
adipose | 100% | 145.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 151.44 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 3.32 | 29 / 29 |
spleen | 100% | 205.90 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.84 | 1 / 1 |
heart | 100% | 111.01 | 857 / 861 | 0% | 0 | 0 / 0 |
muscle | 95% | 59.05 | 765 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 2.06 | 75 / 80 |
peripheral blood | 92% | 96.26 | 853 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 58% | 0.99 | 26 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000649 | Biological process | regulation of sodium ion transmembrane transporter activity |
GO_0042391 | Biological process | regulation of membrane potential |
GO_0098909 | Biological process | regulation of cardiac muscle cell action potential involved in regulation of contraction |
GO_0032527 | Biological process | protein exit from endoplasmic reticulum |
GO_0098905 | Biological process | regulation of bundle of His cell action potential |
GO_0002027 | Biological process | regulation of heart rate |
GO_2000010 | Biological process | positive regulation of protein localization to cell surface |
GO_0003254 | Biological process | regulation of membrane depolarization |
GO_0090307 | Biological process | mitotic spindle assembly |
GO_1903078 | Biological process | positive regulation of protein localization to plasma membrane |
GO_0060047 | Biological process | heart contraction |
GO_1900825 | Biological process | regulation of membrane depolarization during cardiac muscle cell action potential |
GO_0006606 | Biological process | protein import into nucleus |
GO_0006888 | Biological process | endoplasmic reticulum to Golgi vesicle-mediated transport |
GO_1902305 | Biological process | regulation of sodium ion transmembrane transport |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005791 | Cellular component | rough endoplasmic reticulum |
GO_0005901 | Cellular component | caveola |
GO_0014704 | Cellular component | intercalated disc |
GO_0005634 | Cellular component | nucleus |
GO_0005085 | Molecular function | guanyl-nucleotide exchange factor activity |
GO_0031267 | Molecular function | small GTPase binding |
GO_0044325 | Molecular function | transmembrane transporter binding |
GO_0017080 | Molecular function | sodium channel regulator activity |
Gene name | RANGRF |
Protein name | Ran guanine nucleotide release factor (RanGNRF) (Ran-binding protein MOG1) |
Synonyms | HSPC236 MDS5 HSPC165 MOG1 RANGNRF |
Description | FUNCTION: May regulate the intracellular trafficking of RAN . Promotes guanine nucleotide release from RAN and inhibits binding of new GTP by preventing the binding of the RAN guanine nucleotide exchange factor RCC1 . Regulates the levels of GTP-bound RAN in the nucleus, and thereby plays a role in the regulation of RAN-dependent mitotic spindle dynamics . Enhances the expression of SCN5A at the cell membrane in cardiomyocytes . . |
Accessions | ENST00000439238.3 [Q9HD47-3] ENST00000580434.5 [Q9HD47-4] ENST00000407006.8 [Q9HD47-2] Q9HD47 ENST00000226105.11 [Q9HD47-1] |